Neonatal brain-directed gene therapy rescues a mouse model of neurodegenerative CLN6 Batten disease.

The neuronal ceroid lipofuscinoses (NCLs), more commonly referred to as Batten disease, are a group of inherited lysosomal storage disorders that present with neurodegeneration, loss of vision and premature death. There are at least 13 genetically distinct forms of NCL. Enzyme replacement therapies and pre-clinical studies on gene supplementation have shown promising results for NCLs caused by lysosomal enzyme deficiencies. The development of gene therapies targeting the brain for NCLs caused by defects in transmembrane proteins has been more challenging and only limited therapeutic effects in animal models have been achieved so far. Here, we describe the development of an adeno-associated virus (AAV)-mediated gene therapy to treat the neurodegeneration in a mouse model of CLN6 disease, a form of NCL with a deficiency in the membrane-bound protein CLN6. We show that neonatal bilateral intracerebroventricular injections with AAV9 carrying CLN6 increase lifespan by more than 90%, maintain motor skills and motor coordination and reduce neuropathological hallmarks of Cln6-deficient mice up to 23 months post vector administration. These data demonstrate that brain-directed gene therapy is a valid strategy to treat the neurodegeneration of CLN6 disease and may be applied to other forms of NCL caused by transmembrane protein deficiencies in the future.

[1]  T. Melzer,et al.  Longitudinal In Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  E. Henckaerts,et al.  AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann–Pick type C1 disease , 2018, Human molecular genetics.

[3]  Kevin Mills,et al.  Fetal gene therapy for neurodegenerative disease of infants , 2018, Nature Medicine.

[4]  A. Pshezhetsky,et al.  A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency , 2018, Brain : a journal of neurology.

[5]  M. Rizzi,et al.  Prevention of Photoreceptor Cell Loss in a Cln6nclf Mouse Model of Batten Disease Requires CLN6 Gene Transfer to Bipolar Cells. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  E. L. West,et al.  Assessment of AAV Vector Tropisms for Mouse and Human Pluripotent Stem Cell-Derived RPE and Photoreceptor Cells. , 2018, Human gene therapy.

[7]  Brian K. Kaspar,et al.  Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[8]  Kathleen A. Marshall,et al.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial , 2017, The Lancet.

[9]  A. Davidoff,et al.  Advances in Gene Therapy for Hemophilia. , 2017, Human gene therapy.

[10]  W. Pavan,et al.  Systemic AAV9 gene therapy improves the lifespan of mice with Niemann-Pick disease, type C1 , 2016, Human molecular genetics.

[11]  Megan E Bosch,et al.  Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) , 2016, The Journal of Neuroscience.

[12]  A. Biffi.  Gene therapy for lysosomal storage disorders: a good start. , 2016, Human molecular genetics.

[13]  D. Pearce,et al.  Cell biology of the NCL proteins: What they do and don't do. , 2015, Biochimica et biophysica acta.

[14]  S. Berkovic,et al.  Electroclinical spectrum of the neuronal ceroid lipofuscinoses associated with CLN6 mutations , 2015, Neurology.

[15]  S. E. Barker,et al.  Long-term effect of gene therapy on Leber's congenital amaurosis. , 2015, The New England journal of medicine.

[16]  D. Pearce,et al.  Finding the most appropriate mouse model of juvenile CLN3 (Batten) disease for therapeutic studies: the importance of genetic background and gender , 2015, Disease Models & Mechanisms.

[17]  Michael Recht,et al.  Long-term safety and efficacy of factor IX gene therapy in hemophilia B. , 2014, The New England journal of medicine.

[18]  Stacy D. Grunke,et al.  Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction. , 2014, Journal of visualized experiments : JoVE.

[19]  R. Crystal,et al.  Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene. , 2014, Human gene therapy.

[20]  J. Cooper,et al.  A Murine Model of Variant Late Infantile Ceroid Lipofuscinosis Recapitulates Behavioral and Pathological Phenotypes of Human Disease , 2013, PloS one.

[21]  J. Mink,et al.  NCL diseases - clinical perspectives. , 2013, Biochimica et biophysica acta.

[22]  Edith T. Lopez,et al.  Large-Scale Phenotyping of an Accurate Genetic Mouse Model of JNCL Identifies Novel Early Pathology Outside the Central Nervous System , 2012, PloS one.

[23]  J. Cooper,et al.  Disruption of the Autophagy-Lysosome Pathway Is Involved in Neuropathology of the nclf Mouse Model of Neuronal Ceroid Lipofuscinosis , 2012, PloS one.

[24]  M. Schweizer,et al.  High expression of disease‐related Cln6 in the cerebral cortex, purkinje cells, dentate gyrus, and hippocampal ca1 neurons , 2012, Journal of neuroscience research.

[25]  Adem Can,et al.  The tail suspension test. , 2011, Journal of visualized experiments : JoVE.

[26]  J. Cooper,et al.  Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  Katherine R. Smith,et al.  Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6. , 2011, American journal of human genetics.

[28]  M. Souweidane,et al.  Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. , 2008, Human gene therapy.

[29]  Sandra Codlin,et al.  CLN6, which is associated with a lysosomal storage disease, is an endoplasmic reticulum protein. , 2004, Experimental cell research.

[30]  R. Schultz,et al.  The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein. , 2002, American journal of human genetics.

[31]  J. Haines,et al.  Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. , 2002, American journal of human genetics.

[32]  L. Donahue,et al.  Neuronal ceroid lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9. , 1998, American journal of medical genetics.

[33]  E. Neufeld,et al.  Inborn errors of mucopolysaccharide metabolism. , 1970, Science.

[34]  R. Ali,et al.  Gene Therapy Approaches to Treat the Neurodegeneration and Visual Failure in Neuronal Ceroid Lipofuscinoses. , 2018, Advances in experimental medicine and biology.

[35]  S. Mole,et al.  The neuronal ceroid lipofuscinoses : batten disease , 2015 .